VRDN
Viridian Therapeutics, Inc.\DE
$20.20
+0.34 (+1.71%)
At close · Jul 9
Market Cap
$2.03B
Shares
103,074,740
Price & Indicators
Indicators
Price
Panels
Event markers
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$20.20
Open$19.71
Day$19.64–20.24
52W$13.18–34.29
Avg vol 30d2.2M
Short int17.3M · 16.8% float · 5.6d
Short vol71%
Last earningsMay 5, 2026
DataJan 2020–Jul 2026
Filing10-Q · May 5
Up next
Next earnings call
Aug 4, 2026
Est · unconfirmed
· in 3 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 5, 2026
Equibles Rating
blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical
Neutral
Momentum
Weak
Sentiment
Neutral
Fundamentals
Weak
Quant / Vol
Very High
Market backdrop
VIX 15 · calm
Equity put/call 0.55
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−16%
below
Price vs 50-day avg
+19%
above
RSI (14)
66
neutral
MACD trend
Positive
52-week position
33%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+24%
trailing
6-month return
−40%
trailing
YTD return
−35%
this year
Relative strength
−49%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $17 › 200d $24 — 200d above 50d
Institutional flow
Distributing
7 of 225 funds reported for Jun 30 · net -21.4K sh shares
Insider flow
Accumulating
Net +$20.0M over 90 days · 0% sells
Short interest
Rising
16.83% of float · ▲ +15.5% MoM · 5.6 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
225 holders — near 3-yr high, broad support
Squeeze score
67
elevated · 0–100
Fundamentals
Revenue growth
−12%
Y/Y
EPS growth
−31%
Y/Y
Free cash flow
$-276.9M
Balance sheet
$12.4M
net cash
Quant / Vol
risk profile
Volatility
72%
annualized · 1-yr
Max drawdown
−61%
past year
ATR
4.7%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−16%
Bearish
Price vs 50-day avg
+19%
Bullish
RSI (14)
66
Neutral
MACD trend
Positive
Bullish
52-week position
33%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $17 › 200d $24 — 200d above 50d
Institutional flow
Distributing
7 of 225 funds reported for Jun 30 · net -21.4K sh shares
Insider flow
Accumulating
Net +$20.0M over 90 days · 0% sells
Short interest
Rising
16.83% of float · ▲ +15.5% MoM · 5.6 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
225 holders — near 3-yr high, broad support
Price context
position in its 52-week range
52-wk low $13
Now $20 · 33%
52-wk high $34
vs 200-day avg -16%
vs 50-day avg +19%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
VRDN
this stock
Viridian Therapeutics, Inc.\DE
|
$2.03B | -35.1% | -12.0% | — | 16.8% |
|
ONC
BeOne Medicines Ltd.
|
$431.70B | -1.7% | +22179.2% | 878.5 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$123.19B | +9.5% | +46.2% | 28.8 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$69.63B | -13.8% | +20.8% | 16.2 | 3.3% |
|
ARGX
Argenx SE
|
$54.85B | +8.2% | — | — | 2.3% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| VRDN | +9.3% | +23.9% | -40.2% | +10.0% | -35.1% |
| SPY | +0.8% | +2.0% | +8.9% | +0.7% | +10.2% |
| vs SPY | +8.5% | +21.9% | -49.1% | +9.3% | -45.3% |